Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
0.00%
)
Bitcoin
78,874.22
(
0.25%
)
News Focus
News Focus
Post# of 257484
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122926
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 76245

Monday, 04/20/2009 2:18:19 PM

Monday, April 20, 2009 2:18:19 PM

Post# of 257484
VRUS – dewophile, genisi et al: We’ll no longer be able to evaluate VRUS’ (probably bogus) claims that Clevudine was uniquely able to generate SVR’s. I never bought the company’s grandiose assertions about Clevudine’s MoA (#msg-36818344, #msg-36818563), but it would’ve been nice to know one way or the other.

VRUS is down only 11% today; investors evidently hadn’t ascribed much value to Clevudine relative to VRUS’ programs in HCV.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today